menu
    • menu
    [{"orgOrder":0,"company":"Ichnos Glenmark Innovation","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"GRC 65327","moa":"cbl-b","graph1":"Oncology","graph2":"Preclinical","graph3":"Ichnos Glenmark Innovation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ichnos Glenmark Innovation \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Ichnos Glenmark Innovation \/ National Cancer Institute"},{"orgOrder":0,"company":"Ichnos Glenmark Innovation","sponsor":"Certara","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"ISB 2001","moa":"CD38","graph1":"Oncology","graph2":"Phase I","graph3":"Ichnos Glenmark Innovation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ichnos Glenmark Innovation \/ Certara","highestDevelopmentStatusID":"6","companyTruncated":"Ichnos Glenmark Innovation \/ Certara"}]

    Find Clinical Drug Pipeline Developments & Deals by Ichnos Glenmark Innovation

    Menu

    Ichnos Glenmark Innovation

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Ichnos Glenmark Innovation

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Ichnos Glenmark Innovation

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GRC 65327

    Therapeutic Area : Oncology

    Study Phase : Preclinical

    Sponsor : National Cancer Institute

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    IGI and NCI Partner to Test Oral Cbl/b Inhibitor in Triple Negative Breast Cancer

    Details : Under the agreement, IGI and NCI will collaborate on evaluating IGI's proprietary Cbl/b small molecule, GRC 65327, for treating triple-negative breast cancer.

    Product Name : GRC 65327

    Product Type : Other Small Molecule

    Upfront Cash : Undisclosed

    September 30, 2024

    Lead Product(s) : GRC 65327

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Sponsor : National Cancer Institute

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Ichnos Glenmark Innovation

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Ichnos Glenmark Innovation

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ISB 2001

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Certara

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Certara and Ichnos Glenmark Collaborate On Cancer Drug Dosing Optimization

    Details : ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.

    Product Name : ISB 2001

    Product Type : Antibody

    Upfront Cash : Undisclosed

    September 18, 2024

    Lead Product(s) : ISB 2001

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Certara

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth